Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect

Nathan Suek 1, Luis Felipe Campesato 1, Taha Merghoub 1,2* and Danny N. Khalil 1,2*

1 Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 2 Department of Medicine, Weill Cornell Medical College, New York, NY, United States

In oncology, the “abscopal effect” refers to the therapeutic effect on a distant tumor resulting from the treatment of local tumor (e.g., ablation, injection, or radiation). Typically associated with radiation, the abscopal effect is thought to be mediated by a systemic antitumor immune response that is induced by two concurrent changes at the treated tumor: (1) the release of tumor antigens and (2) the exposure of damage-associated molecular patterns. Therapies that produce these changes are associated with immunogenic cell death (ICD). Some interventions have been shown to cause an abscopal effect without inducing the release of tumor antigens, suggesting that release of tumor antigens at baseline plays a significant role in mediating the abscopal effect. With tumor antigens already present, therapies that target activation of APCs alone may be sufficient to enhance the abscopal effect. Here, we discuss two therapies targeted at APC activation, TLR9 and CD40 agonists, and their use in the clinic to enhance the abscopal effect.

Keywords: abscopal effect, APC activation, DC, immunogenic cell death (ICD), CD40L, TLR9

INTRODUCTION

The abscopal effect (derived from the Latin “ab” meaning away from and “scopus” meaning target) refers to the local destruction of a tumor which results also in the regression of a distant tumor. The phenomenon has been well-described in pre-clinical models, often in the context of radiation. For example, when combined with Flt3-L, irradiation not only resulted in control of the primary tumor but also of a non-irradiated secondary tumor (1). Though described in pre-clinical settings, the abscopal effect is still relatively rare in patients. In one study of 34 patients with metastatic prostate cancer, treatment with radiation and the immunotherapy, ipilimumab, resulted in a complete response at local and distant tumors for one patient (3%) (2). Ionizing radiation (IR) is thought to induce the abscopal effect via two changes at the treated tumor: (1) release of tumor associated antigens (TAAs) and (2) release of damage associated molecular patterns (DAMPs) which activate antigen presenting cells (APCs). We will examine the relative contribution of both factors to the abscopal effect and the role of IR in inducing each.

RELEASE OF ANTIGENS AND EXPOSURE OF DAMPS

IR damages a tumor cell’s DNA which can result in ICD. In ICD, the tumor cell releases antigen and enhances phagocytosis by APCs through signals like calreticulin, which facilitates phagocytosis, and
ATP, which attracts APCs (3). The net result is the presentation of tumor antigens by APCs. While tumor cells have been reported to act as antigen presenting cells, we will use the term APC to refer to professional APCs such as dendritic cells (DC) and macrophages. However, antigen presentation by immature DCs can lead to T cell tolerance as T cells become anergic, suppressive, or are simply deleted (4). To mediate the abscopal effect, radiation is thought not only to release tumor antigens but also DAMPs that activate APCs. DAMPs include HMGB1, ATP, and non-nuclear DNA (3). While DAMPs exert their effects by various mechanisms, they converge on the same functional outcome: activation of APCs that can initiate an adaptive immune response.

It is important to consider the relative contributions of both the release of tumor antigens and of DAMPs to the abscopal effect. During tumor growth, antigens from malignant cells undergoing chronic turnover are engulfed by DCs. However, DAMPs may not be released in sufficient quantities to consistently mature them (5, 6). For example, in a study by Vicari et al. tumor infiltrating dendritic cells (TIDCs) at baseline were shown to present antigen albeit in an immature state. Upon treatment with CpG and IL10R blocking antibody to activate TIDCs, tumors were regressed by an adaptive immune response (6). Given the presence of tumor antigens in the microenvironment, interventions that activate APCs without releasing additional antigens may be sufficient to initiate a systemic immune response and abscopal effect. Considering the rarity of the abscopal effect with radiation, other therapies that promote DC activation in a targeted manner may increase its frequency (7) (Figure 1). Here, we discuss TLR9 and CD40 as promising therapeutic targets to enhance DC activation and summarize their progress in clinical development.

**TLR9**

Modern cancer immunotherapy arguably began with Dr. William Coley’s intratumoral injections of bacterial lysates, derisively called “Coley’s toxin.” It was later determined that bacterial DNA
within these lysates, specifically the CpG sequence motif, was
the component responsible for eliciting an immune response
(8). Unmethylated cytosine-phosphate-guanine (CpG) binds
to TLR9 which, in humans, is expressed primarily by (1) B cells
and (2) plasmacytoid dendritic cells (pDCs) (9). TLR9 signals
through each cell type to initiate a differing cascade of immune
effects. TLR9 activation on B cells enhances their differentiation
into antibody-secreting plasma cells (10). TLR9 activation on
pDCs results in several effects: (1) secretion of type-1 interferons
(4) (2) secretion of Th1 type cytokines (e.g., TNFα, IFNγ, IL2)
(10) (3) expression of TNF-related apoptosis-inducing ligand
(TRAIl) which can induce tumor cell death directly (9) and (4)
expression of co-stimulatory molecules (e.g., CD80, CD86) and
lymph node homing signal CCR7 (9). While the APC function
of pDCs is debated (11), pDC secretion of type-1 interferons,
primarily IFNα, is thought to be the dominant effect by which
TLR9 signaling induces antitumor immunity (10). IFNα has
direct effects on tumors including the inhibition of angiogenesis
(12), antiproliferative effects (13), as well as increased MHC I
expression and thus enhanced immunogenicity (13). Its effect
on immune cells include the enhanced ability of NK cells to kill
and produce IFNγ as well as the maturation of conventional DCs
(13). The ability to mature DCs is particularly appealing as a
therapy to enhance the abscopal effect.

Interest in the clinical use of TLR9 agonists has waxed and
waned throughout the years. In mouse studies, therapies
involving CpG have induced extremely potent abscopal responses,
often resulting in complete regression of treated
as well as distant, non-treated tumors (6, 14–16). Early
human data was also promising. As monotherapy, TLR9 agonists
have been shown in several phase I and II to result in objective
responses, and even some complete responses, in cutaneous T
cell lymphoma (17), basal cell carcinoma (18), and melanoma
(18). However, in two phase III trials for advanced NSCLC,
TLR9 in combination with either chemotherapy regimens
paclitaxel/carboplatin (19) or gemcitabine/cisplatin (20) did
not extend overall survival compared to chemotherapy alone.
In fact, addition of TLR9 resulted in increased adverse effects
which led to early discontinuation of TLR9 administration in
those studies. Interest in TLR9 faltered after these trials and
efforts were scaled back on CpG agents like PF-3512676 (10).
The discrepancy between the promising preclinical data and
disappointing clinical results may be partially attributed to the
broad expression of TLR9 in mice (in nearly all myeloid cells)
compared to narrow expression in humans (primarily B cells
and pDCs) (8).

With the recent successes of immune checkpoint blockade,
there has been renewed interest in TLR9 agonists for their
potential in combination therapies with T cell activating agents.
Various combinations are currently being tested in clinical trials
and are detailed in Table 1. These trials improve upon past
trials of such agents for at least two reasons (21). First, whereas
previous failed trials (19, 20) used subcutaneous systemic
administration, current trials often focus on intratumoral
injection (e.g., NCT03410901, NCT03445533). Intratumoral
injection is thought to increase potency while also avoiding
systemic toxicity. Indeed, one CpG agent has been shown
to regress tumors when given intratumorally (7) whereas the
same drug had little to no effect when given systemically
(22). Second, the impact of TLR9 agonists in the past may
have been curtailed by negative feedback mechanisms such as
increased PD-1 signaling. Ongoing trials combining TLR9 with
ipilimumab (8) and pembrolizumab (23) attempt to address
these barriers. Recent trials (23, 24) employing these strategies
have been well-tolerated while regressing local, treated tumors,
and untreated, abscopal tumors. Such studies merit further
investigation to further elucidate the effectiveness of CpG for
inducing systemic immunity.

### CD40

The TNF superfamily receptor CD40 is expressed on
hematopoietic cells such as DCs, B cells, monocytes, and
macrophages, non-hematopoietic cells such as epithelial cells
and fibroblasts, as well as tumor cells in melanoma and lung
cancer (25). Its ligand, CD40L, is expressed by CD4 T cells.
Ligation of CD40 results in activation of the cell on which
it is expressed (26). On B cells, CD40 signaling results in class
switching, somatic hypermutation, formation of long lived
plasma, and memory cells (25), and enhanced antigen presenting
function (27). On DCs, CD40 signaling results in upregulation
of costimulatory molecules (e.g., CD80, CD86), production of

| Drug     | Developer       | Conditions             | Combination | Clinical trials          |
|----------|-----------------|------------------------|-------------|--------------------------|
| SD-101   | Dynavax         | B cell Hodgkin’s       | Anti-OX40 Ab | NCT03410901              |
|          |                 | Lymphoma               | (BM3 986178) Radiation |                       |
|          |                 | B cell Lymphoma        | SD-101      | NCT02254772              |
|          |                 |                        | Ipilimumab  |                         |
|          |                 |                        | Radiation   |                         |
| Melanoma |                 | Head and neck squamous | SD-101      | NCT02521870              |
|          |                 | cell carcinoma         | Ipilimumab  |                         |
|          |                 |                        | Radiation   |                         |
| Lymphoma |                 |                        | SD-101      | NCT03322384              |
|          |                 |                        | Epacadostat |                         |
|          |                 |                        | Radiation   |                         |
| IMO-2125 | Idera           | Melanoma               | IMO-2125    | NCT03445533              |
|          |                 |                        | Ipilimumab  |                         |
|          |                 |                        |IMO-2125/     |                         |
|          |                 |                        | Ipilimumab/  |                         |
|          |                 |                        | Pembrolizumab|                         |
|          |                 |                        | Radiation   |                         |
|          | Checkmate       | Melanoma               | CMP-001     | NCT03084640              |
|          | Pharmaceuticals |                        | Melanoma    |                         |
|          |                 |                        | CMP-001     | NCT03618641              |
|          |                 |                        | Nivolumab   |                         |
|          |                 |                        | Radiation   |                         |
| NSCLC    |                 |                        | NSCLC       | NCT03438318              |
|          |                 |                        | CMP-001     |                         |
|          |                 |                        | Atezolizumab|                         |
|          |                 |                        | Radiation   |                         |
| MGN1703  | Molgen          | Advanced solid cancers | MGN1703     | NCT02668770              |
|          |                 |                        | Ipilimumab  |                         |

A selection of clinical trials of interest are shown. Information compiled from clinicaltrials.gov.
cytokines (e.g., IL-12) (26), enhanced expression and stability of MHC, and increased expression of factors which promote survival (e.g., Bcl-XL) (25). CD40 signaling occurs through two categories of adapter protein: (1) TNFR-associated factors (TRAFs) and (2) Jak family kinase 3 (JAK3). This leads to activation of various signaling pathways including MAPK, PI3K, PLCγ, and NF-κB. Details of these signaling pathways have been described elsewhere (25).

In preclinical models, agonist CD40 antibodies have been shown to be effective at regressing tumors (28, 29). The mechanism of agonist CD40 antibodies can be subdivided into T cell independent and dependent effects. The T cell independent effects include direct apoptotic signaling on CD40+ tumors (30), targeting of CD40+ tumors for ADCC or complement-dependent cytotoxicity (CDC), and activation of other effector cells including NK cells (31) and macrophages (32) to regress tumors. The T cell dependent effects are mediated by activation of APCs which allow them to prime tumor specific CD8 T cells. In treatment with anti-CD40 mAb, depletion of CD4 T cells does not affect efficacy, suggesting that the CD40 mAb replaces the need for CD40L from helper T cells (33).

While no anti-CD40 antibodies have been approved by the FDA, several are in active clinical development and detailed in Table 2. In the clinic, CD40 agonists have had moderate therapeutic activity. CD40 agonist, CP-870,893 as single agent has resulted in 14% objective response rate in a study of advanced solid cancers (34). Of note, one of these patients with melanoma went on to have a complete response that has lasted over a decade (26). However, in another study of advanced solid cancers, single agent CP-870,893 resulted in no clinical benefit (35). In combination with chemotherapy, CP-870,893 has had a 20% response in various advanced solid tumors (36). In the case of metastatic pancreatic cancer, this was higher than response rates with chemotherapy alone (37). Other CD40 agonists such as Chi Lob 7/4 have demonstrated no objective responses in initial clinical studies (27). In terms of toxicity, CD40 agonists have been associated with important adverse effects. For example, CP-870,893 resulted in CRS in a majority of patients and has been the dose limiting toxicity (38). These two issues, moderate efficacy, and toxicity, have hindered the clinical development of CD40 agonists.

To address efficacy, it is important to consider the mechanism by which these antibodies induce agonism. CD40 mAbs require crosslinking (i.e., oligomerization) of the CD40 receptor to induce the agonistic effect. Crosslinking can be enhanced by an in trans interactions between the CD40 mAb Fc region and an Fc receptor (FcR) expressed on a neighboring cell (39). As such, some have worked to improve CD40 agonist activity through Fc engineering to enhance the Fc-FcR interaction (27, 40–43). Others have suggested that the mAb formatted as an IgG2b has a compact hinge structure which may mediate effective crosslinking in the absence of the Fc receptor (44). Current CD40 agonists do not achieve optimal efficacy for several different reasons. Most CD40 agonists have been IgG1 and this human isotype has been shown to bind poorly to FcγRIIb (45), which is thought to be the main Fc receptor that mediates effective crosslinking (33). IgG2 mAb in development include CP-870,893 which shuffles between the IgG2a and IgG2b formats thereby limiting its potency (44). For these reasons, many CD40 agonists, both IgG1 and IgG2, likely fail to achieve their full therapeutic efficacy due to suboptimal crosslinking. Higher order oligomerization of the CD40 receptor (i.e., crosslinking) is thought to result in greater activation of downstream pathways such as NF-κB (46) and drive greater immunostimulation (25). In a preclinical study of recombinant CD40L, forming CD40L into higher order oligomers significantly increased B cell activation (47). Future development of CD40 agonists should focus on achieving efficient clustering to maximize therapeutic efficacy.

To address toxicity, researchers have investigated local injections of CD40 agonists to avoid systemic adverse effects. For example, at the same dose, local injection was superior to systemic administration of CD40 agonists (48) while also reducing biodistribution of the antibody in the liver.

**Table 2** | Selected CD40 agonists in clinical development.

| Drug          | Developer             | Fc     | Conditions                      | Combination                  | Clinical Trials       |
|--------------|----------------------|--------|---------------------------------|------------------------------|-----------------------|
| CP-870,893   | Pfizer/VLST          | IgG2   | Advanced solid tumors           | CP-980,893                   | NCT01103635           |
|              |                      |        | Pancreatic adenocarcinoma       | CP-980,893                   | NCT01456585           |
|              |                      |        |                                 | Gemcitabine                  |                       |
|              |                      |        |                                 | CP-980,893                   |                       |
|              |                      |        | Metastatic solid tumors         | Paclitaxel                   |                       |
|              |                      |        |                                 | Carboplatin                  |                       |
|              |                      |        |                                 | SGN-40                       | NCT00607048           |
| Dacetuzumab  | Seattle Genetics      | IgG1   | Lymphoma                       | SGN-40                       | NCT00435916           |
| Chi Lob 7/4  | University of Southampton | IgG1 | Advanced malignancies           | Chi Lob 7/4                  | NCT01561911           |
| APX005M      | Apexigen             | IgG1   | Melanoma                       | APX005M                      | NCT02706353           |
|              |                      |        |                                 | Pembrolizumab                |                       |
|              |                      |        | Pancreatic adenocarcinoma       | Gemcitabine+Nab-Paclitaxel   |                       |
|              |                      |        |                                 | APX005M                      | NCT03214250           |
|              |                      |        |                                 | Nivolumab                    |                       |

A selection of clinical trials of interest are shown. Information compiled from clinicaltrials.gov.
and possibly hepatotoxicity (38). This superior efficacy of local administration along with decreased toxicity has been demonstrated in multiple tumor models (41, 49–51). Efficacy and toxicity go hand in hand. Increased dosing could be one strategy to compensate for suboptimal efficacy, but in the case of CD40 agonists, this is problematic due to issues with toxicity. Until optimal dosing and route of administration is established, it is unlikely that CD40 agonists will have reached their maximum therapeutic potential (26).

APC ACTIVATION AS PART OF COMBINATION IMMUNOTHERAPIES

As an immunotherapeutic strategy, focusing on antigen presentation represents only one step in mediating a systemic antitumor response. Other aspects—from T cell infiltration to immunosuppression by myeloid cells—remain critical steps for T-cell mediated tumor control. For example, in one study, the efficacy of checkpoint blockade was significant enhanced by combination with PI3K-γ, which switches tumor associated myeloid cells from an immunosuppressive to immunostimulatory phenotype (52). Therefore, combinatorial approaches that target multiple aspects of the cycle are promising strategies for treatment. Future studies that target several aspects of antitumor immunity, including APC activation, are likely to improve patient outcomes in the years ahead.

AUTHOR CONTRIBUTIONS

All authors researched data for article, contributed to discussion of the content, wrote the manuscript and reviewed/edited the article before submission.

FUNDING

This research was funded through the NIH/NCI Cancer Center Support Grant P30 CA008748.

REFERENCES

1. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. (2004) 58:862–70. doi: 10.1016/j.ijrobp.2003.09.012
2. Skolnick SE, Higano CS, Hamid O, Teijwani S, Harzstark A, Alumkal J, et al. Iplimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase ii study. Ann Oncol. (2013) 24:1813–21. doi: 10.1093/annonc/mdt107
3. Pitt JM, Kroeher G, Zitvogel L. Immunogenic and non-immunogenic cell death in the tumor microenvironment. Adv Exp Med Biol. (2017) 1036:65–79. doi: 10.1007/978-3-319-67577-0_5
4. Parker BS, Rautela J. Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. (2016) 16:131–44. doi: 10.1038/nrc4516.2014.14
5. Green DR, Ferguson T, Zitvogel L, Kroeher G. Immunogenic and tolerogenic cell death. Nat Rev Immunol. (2009) 9:533–63. doi: 10.1038/nri2545
6. Vicari AP, Chiodoni C, Vaure C, Ait-Yahia S, Dercamp C, Matsos F, et al. Reversal of tumor-induced dendritic cell paralysis by CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. (2007) 179:2493–500. doi: 10.4049/jimmunol.179.4.2493
7. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. (2010) 28:4324–32. doi: 10.1200/JCO.2010.28.9793
8. Adamus T, Kortylewski M. The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol. (2018) 2018:56–60. doi: 10.5114/wo.2018.73887
9. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest. (2007) 117:1184–94. doi: 10.1172/JCI31414
10. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. (2008) 27:161–7. doi: 10.1038/sj.onc.1210911
11. Villadangos JA, Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity. (2008) 29:352–61. doi: 10.1016/j.immuni.2008.09.002
12. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. (2002) 2:727–39. doi: 10.1038/nrc905
13. Hervas-Stibbs S, Perez-Gracia JL, Rouzaut A, Sammande MF, Le Bon A, Meleo I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res. (2011) 17:2619–27. doi: 10.1158/1078-0432.CCR-10-1114
14. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seidler J, Jahrsdörfer B, et al. Peritumoral CpG DNA elicits a coordinated response of CDB T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol. (2002) 169:3892–9. doi: 10.4049/jimmunol.169.7.3892
15. Li J, Song W, Czerwinskie DK, Vargheese B, Umetani S, Akira S, et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. (2007) 179:2493–500. doi: 10.4049/jimmunol.179.4.2493
16. Houot R, Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood. (2009) 113:3546–52. doi: 10.1182/blood-2008-07-170274
17. Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, et al. Phase I trial of a toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol. (2010) 63:975–83. doi: 10.1016/j.jaad.2009.12.052
18. Hofmann MA, Kors C, Audring H, Walden P, Sterry W, Trefzer U. Phase 1 evaluation of intrasessionally injected TLR9 agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother. (2008) 31:250–7. doi: 10.1097/CJI.0b013e318174a4df
19. Hirsh V, Paz-Ares L, Boyer M, Rosell R, Middleton G, Eberhardt WE, et al. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (tolllike receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. (2011) 29:2667–74. doi: 10.1200/JCO.2010.32.8971
20. Manegold C, van Zandwijk N, Szczesna A, Zatloukal P, Au JS, Blasinska-Morawiec M, et al. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol. (2012) 23:72–7. doi: 10.1093/annonc/mdr030
21. Poh A. Warming ‘cold’ melanoma with TLR9 agonists. Nature. (2018) 560:211–7.
22. Zent CS, Smith BJ, Ballas ZK, Wooldridge JE, Link BK, Call TG, et al. Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Nature. (2012) 53:211–7. doi: 10.1038/nature10428.1914.608451
23. Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, et al. Ipilimumab alone or in combination with radiotherapy in metastatic melanoma in the first-line setting: results from a randomized phase III trial. J Clin Oncol. (2018) 36:1919–29. doi: 10.1200/JCO.2017.78.7015
24. Frank MJ, Reagan PM, Bartlett NL, Gordon LJ, Friedberg JW, Czerwinski DK, et al. In Situ vaccination with a TLR9 agonist and local low-dose radiation...
induces systemic responses in untreated indolent lymphoma. *Cancer Discov.* (2018) 8:1258–69. doi: 10.1108/2159-8290.CD-18-0743

25. Elgueta R, Benson MJ, de Vries VC, Wasuik A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. *Immunol. Rev.* (2009) 229:152–72. doi: 10.1111/j.1600-065X.2009.00872.x

26. Vonderheide RH. The immune revolution: a case for priming, not checkpoint. *Cancer Cell.* (2018) 33:563–9. doi: 10.1016/j.ccell.2018.03.008

27. Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. * Clin Cancer Res.* (2013) 19:1035–43. doi: 10.1158/1078-0432.CCR-12-2064

28. French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. *Nat Med.* (1999) 5:548–53. doi: 10.1038/4826

29. van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offeringa R, et al. CD40 stimulation leads to effective therapy of CD40+ tumors through induction of strong systemic cytotoxic T lymphocyte immunity. *Proc Natl Acad Sci USA.* (2002) 99:5561–6. doi: 10.1073/pnas.082107699

30. Funakoshi S, Longo DL, Beckwith M, Conley DK, Tsarfaty G, Tsarfaty I, et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. *Blood.* (1994) 83:2787–94.

31. Turner JG, Rakhmilevich AL, Burdelya L, Neal Z, Imboden M, Sondel PM, et al. Anti-CD40 antibody induces antitumor and antimitastatic effects: the role of NK cells. *J. Immunol.* (2001) 166:89–94. doi: 10.4049/jimmunol.166.1.89

32. Beatty GL, Chioorean EG, Fishman MP, Samboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. *Science.* (2011) 331:1612–6. doi: 10.1126/science.1198443

33. Remer M, White A, Glennie M, Al-Shamkhani A, Johnson P. The use of anti-CD40 mAb in cancer. *Curr Top Microbiol Immunol.* (2017) 405:165–207. doi: 10.1007/8_2014_427

34. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. *J Clin Oncol.* (2007) 25:876–83. doi: 10.1200/JCO.2006.0.8.3311

35. Witteveen J, Mebius RE, Sluijter M, Morreau H, Arens R, Melief CJ. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. *Clin Cancer Res.* (2011) 17:2270–80. doi: 10.1158/1078-0432.CCR-10-0943

36. Pullen SS, Labadia ME, Ingraham RH, McWhirter SM, Evered DS, Alber T, et al. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. *Biochemistry.* (1999) 38:10166–77. doi: 10.1021/bi9909905

37. Naito M, Hainz U, Burkhardt UE, Fu B, Ahove D, Stevenson KE, et al. CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. *Cancer Immunol Immunother.* (2013) 62:347–57. doi: 10.1007/s00262-012-1331-4

38. Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachv C, Tötterman TH, et al. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. *Cancer Immunol Res.* (2014) 2:80–90. doi: 10.1158/2326-6066.CIR-13-0067

39. Rahimian S, Fransen MF, Kleinoviov JW, Amidio M, Ossendorp F, Hennink WE. Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer. *Biomaterials.* (2015) 61:33–40. doi: 10.1016/j.biomaterials.2015.04.043

40. Manganao SM, Broos S, Fletcher E, Veitomnäki N, Furebring C, Dahlén E, et al. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity. *Clin Cancer Res.* (2015) 21:1113–26. doi: 10.1158/1078-0432.CCR-14-0913

41. Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ. Local activation of CD8+ T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. *Clin Cancer Res.* (2011) 17:2270–80. doi: 10.1158/1078-0432.CCR-10-2888

42. De Henaux O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kδ in myeloid cells. *Nature.* (2016) 539:443–7. doi: 10.1038/nature20554

Conflict of Interest Statement: TM is a consultant for Immunos Therapeutics and Pfizer. TM is a co-founder with equity in IMV AQ therapeutics. TM receives research funding from Bristol-Myers Squibb, Surface Oncology, Kyn Therapeutics, Infinity Pharmaceuticals Inc., Peregrine Pharmaceuticals Inc., Adaptive Biotechnologies, Leap Therapeutics Inc., and Aprea. TM is an inventor on patent applications related to work on Oncolytic Viral therapy, Alpha Virus Based Vaccine, Neo Antigen Modeling, CD40, GITR, OX40, PD-1 and CTLA-4. TM is a co-founder with equity in IMV AQ therapeutics. TM is a consultant for Immunos Therapeutics and Pfizer. TM is a co-founder with equity in IMV AQ therapeutics. TM receives research funding from Bristol-Myers Squibb, Surface Oncology, Kyn Therapeutics, Infinity Pharmaceuticals Inc., Peregrine Pharmaceuticals Inc., Adaptive Biotechnologies, Leap Therapeutics Inc., and Aprea. TM is an inventor on patent applications related to work on Oncolytic Viral therapy, Alpha Virus Based Vaccine, Neo Antigen Modeling, CD40, GITR, OX40, PD-1 and CTLA-4. TM is a consultant for Merck.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.